Hypersensitivity reactions associated with oxaliphatin

Expert Opinion on Drug Safety

Volumn 5, Issue 5, 2006, Pages 687-694

  Saif, M Wasif ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaphylaxis; Antihistamine; Colon cancer; Desensitisation; Fever; Hypersensitivity reaction; Oxaliphatin; Rash; Steroid

Indexed keywords

ADRENALIN; BEVACIZUMAB; CARBOPLATIN; CIMETIDINE; CISPLATIN; CLARITHROMYCIN; DEXAMETHASONE; DIPHENHYDRAMINE; DIPYRONE; FAMOTIDINE; FLUOROURACIL; FOLINIC ACID; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HLA ANTIGEN; IMMUNOGLOBULIN E; INTERLEUKIN 6; IRINOTECAN; LORAZEPAM; METHYLPREDNISOLONE; METOCLOPRAMIDE; MITOMYCIN C; ONDANSETRON; OXALIPLATIN; OXYGEN; PLATINUM DERIVATIVE; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ANAPHYLACTIC SHOCK; BRONCHOSPASM; BURNING SENSATION; CHILL; CLINICAL FEATURE; CLINICAL PROTOCOL; COHORT ANALYSIS; COLORECTAL CANCER; DESENSITIZATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG UTILIZATION; DYSPNEA; EDEMA; ERYTHEMA; FEVER; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; INCIDENCE; MALIGNANT NEOPLASTIC DISEASE; MUSCLE WEAKNESS; PATHOPHYSIOLOGY; PRURITUS; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN TEST; TACHYCARDIA; TONGUE SWELLING; URTICARIA; VALIDATION STUDY; VOMITING; COLORECTAL TUMOR; EXPERT WITNESS; FEMALE; METASTASIS; MIDDLE AGED;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG HYPERSENSITIVITY; EXPERT TESTIMONY; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SKIN TESTS;

EID: 33747501796     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.5.687     Document Type: Review

References (33)

1. GOLDBERG RM, SARGENT DJ, MORTON RF et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. (2004) 22(1):23-30.
2. ANDRE T, BONI C, MOUNEDJI-BOUDIAF L et al.: Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. (2004) 350(23):2343-2351.
3. SHEPHERD GM: Hypersensitivity reactions to chemotherapeutic drugs. Clin. Rev. Allergy Immunol. (2003) 24:253-262
4. ROBINSON JB, SINGH D, BODURKA-SEVERS DC et al.: Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol. Oncol. (2001) 82:550-558.
5. THOMAS RR, QUINN MG, SCHULER B et al.: Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer (2003) 97:2301-2307.
6. BRANDI G, PANTALEO MA, GALLI C et al.: Hypersensitivity reactions related to oxaliplatin (OHP). Br. J. Cancer (2003) 89(3):477-481.
7. MEYER L, ZUBERBIER T, WORM M et al.: Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J. Clin. Oncol. (2002) 20:1146-1147.
8. QURESHI KM: Incidence of hypersensitivity reactions to oxaliplatin at Roswell Park Cancer Institute (RPCI) and protocol for desensitization. Proc. Am. Soc. Clin. Oncol. (2003) 22:789.
9. SIU SW, CHAN RT, AU GK: Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann. Oncol. (2006) 2:259-261.
10. MAINDRAULT-GOEBEL F, ANDRE T, TOURNIGAND C et al.: Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur. J. Cancer (2005) 41(15):2262-2267.
11. ULRICH-PUR H, FIEBIGER WCC, SCHULL B, KORNEK GV et al.: Oxaliplatin-induced fever and release of IL-6. Oncology (2000) 59:187-189.
12. KOREN C, YERUSHALMI R, KATZ A et al.: Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am. J. Clin. Oncol. (2002) 25(6):625-626.
13. BASU R, RAJKUMAR A, DATTA NR et al.: Anaphylaxis to cisplatin following nine previous uncomplicated cycles. Int. J. Clin. Oncol. (2002) 7(6):365-367.
14. POLYZOS A, TSAVARIS N, KOSMAS C et al.: Hypersensivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology (2001) 61:129-133.
15. STAHL M, KOSTER W, WILKE H: Reaction after oxaliplatin-prevention with corticosteroids? Ann. Oncol. (2001) 12(1):132-133.
16. SANTINI D, TONINI G, SALERNO A et al.: Idiosyncratic reactions after oxaliplatin infusion. Ann. Oncol. (2001) 12:132-133.
17. HETHERINGTON S, HUGHES AR, MOSTELLER M et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet (2002) 359:1121-1122.
18. NEWMAN TAYLOR AJ, CULLINAN P, LYMPANY PA et al.: Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts. Am. J. Resp. Crit. Care Med. (1999) 160:435-438.
19. ESCALANTE CP, OH JH, BAUM DD et al.: Immediate adverse reactions to chemotherapy: experience of a large ambulatory treatment center. J. Clin. Oncol. (2006) 24(18S Suppl.):8558.
20. MARKMAN M, ZANOTTI K, PETERSON G et al.: Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J. Clin. Oncol. (2003) 21:4611-4614.
21. GARUFI C, CRISTAUDO A, VANNI B et al.: Skin testing and hypersensitivity reactions to oxaliplatin. Ann. Oncol. (2003)14:497-498.
22. BHARGAVA P, GAMMON D, MCCORMICK MJ: Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer (2004) 100:211-212.
23. WINDOM HH, MCGUIRE WP 3rd, HAMILTON RG et al.: Anaphylaxis to carboplatin - a new platinum chemotherapeutic agent. J. Allergy Clin. Immunol. (1992) 90:681-683.
24. GOLDBERG A, CONFINO-COHEN R, FISHMAN A et al.: A modified, prolonged desensitization protocol in carboplatin allergy. J. Allergy Clin. Immunol. (1996) 98:841-843.
25. MIS L, FERNANDO NH, HURWITZ H et al.: Successful desensitization to oxaliplatin. Ann. Pharmacother. (2005) 39:966-968.
26. LIM KH, HUANG MJ, LIN HC et al.: Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. Anti-Cancer Drugs (2004) 15(6):605-607.
27. AROTCARENA R, BERTHELEMY P, PIOT M et al.: Readministration of oxaliplatin using a rapid desensitization method after severe anaphylactic reaction. Gastroenterol. Clin. Biol. (2001) 25(2):206-207.
28. GAMMON D, BHARGAVA P, MCCORMICK MJ: Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist (2004) 9(5):546-549.
29. RAKKAR AS: SC Epinephrine to ameliorate HSR related to oxaliplatin. Proceedings of GI ASCO, San Francisco, CA, USA (2006):Abstr. 258.
30. SAIF MW, REARDON J: Management of oxaliplatin-induced peripheral neuropathy. Ther. Clin. Risk Manage. (2005) 1(4):249-258.
31. SAIF MW: Oral calcium ameliorating oxaliplatin-induced peripheral neuropathy. J. Appl. Res. (2004) 4(4):576-582.
32. GROTHE W, ARNOLD D, PEINERT S et al.: Cetuximab with oxaliplatin and capecitabine (CAPOX) in patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy. J. Clin. Oncol. (2005) 23(165):Abst. 3669.
33. DAKHIL S, COSGRIFF T, HEADLEY D et al.: Cetuximab + FOLFOX6 as first line therapy for metastatic colorectal cancer (an International Oncology Network study, I-03-002). J. Clin. Oncol. (2006) 24(18S):Abstr. 3557.